Floatz logo

Metformin

Li-Fraumeni Syndrome

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Li-Fraumeni Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 2B
Evomela
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Glofitamab
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Azacitidine
The First Affiliated Hospital of Xiamen University
Phase 2CCC
cc-5013
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC

View all 18 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →